Portail HAL de l'Université Picardie Jules Verne
Not a member yet
32425 research outputs found
Sort by
EDUCAUSE 2025 Rapport de la délégation française - FR: Visites de Vanderbilt University Arizona State University
No full textDepuis douze ans maintenant, la Délégation Française EDUCAUSE propose à la communauté del’Enseignement Supérieur français une ouverture à l’international sur les enjeux du numérique, en associantdes profils complémentaires à même d’en apprécier les tendances fortes et les perspectives majeures. Cettedémarche s’est ainsi concrétisée par une participation continue aux conférences EDUCAUSE depuis 2013,qui s’est très significativement enrichie au cours des années. D’une philosophie initiale de simpleparticipation, les membres de cette Délégation se sont en effet progressivement impliqués à différentsniveaux d’EDUCAUSE, dans le cadre des conférences et au-delà (voir l’infographie ci-dessous).La Délégation totalise vingt-quatre présentations sélectionnées, sur plusieurs sujets d’actualité. Plusieurs denos membres, par ailleurs, sont mobilisés chaque année en tant que proposal reviewers (relecteurs depropositions d’interventions) pour la conférence EDUCAUSE, mais aussi en tant que membres des comitésde programme respectifs (en 2019, 2023 et 2026). Enfin, certains d’entre nous font partie des panelsd’experts mobilisés dans le cadre du EDUCAUSE Horizon Report et du Top-10 issues annuels, sont actifs ausein de différents Community Groups thématiques (XR et Learning Spaces en particulier), ou s’impliquent entant que rédacteurs d’articles de référence et traducteurs d’outils.Mentionnons également ici les plus de trente visites de sites qui ont été menées depuis 2013 avant ou aprèsles conférences EDUCAUSE et qui, au-delà du remarquable accueil qui nous a toujours été réservé, nous ontapporté une vue de terrain très précieuse au travers d’échanges de grande qualité
[Note de lecture] Front Unique. L’art en acte : les dispositifs insoumis de Jean-Jacques Lebel: Jérôme Duwa, Front Unique. La traversée du surréalisme de Jean-Jacques Lebel, Dijon : Les presses du réel/Rhizomeditions, 2024, 333 p., EAN 9782378965372
No full textInternational audienceLe livre Front Unique dépasse largement la simple restitution d’un travail sur des archives. C’est une traversée, au sens fort du terme, dans l’univers intellectuel, politique et artistique de Jean-Jacques Lebel. En mettant en lumière la revue Front Unique (1955–1960), Jérôme Duwa donne accès à une constellation d’expériences, de filiations et de révoltes qui traversent l’après-guerre européen. Plus encore, le livre permet surtout de comprendre comment Jean-Jacques Lebel, en tant que figure inclassable, relie poésie, activisme, pensée politique et pratiques artistiques inédites, en adoptant une posture de circulation critique et en refusant tout cloisonnement idéologique. « Je suis ce que je suis parce que je me suis construit par désir, par contacts directs, par rencontres désirées, bref, en autodidacte » (p. 224), dit Jean-Jacques Lebel et donne le ton de son aventure artistique et intellectuelle. Ce n’est peut-être pas tout à fait anecdotique que ce soit à Florence, en travaillant comme stagiaire à la restauration du Déluge, la fresque d’Ucello, qu’il s’intéresse aux techniques de la peinture. « Avec ce stage à la Santa Maria Novella et au Palazzo Pitti, je suis finalement initié, dit-il, physiquement et mentalement à la peinture » (p. 226). C’est ainsi véritablement dans le faire, dans le contact des êtres, des choses et des matières que le jeune artiste Jean-Jacques Lebel commence à se former
Tailored BiFeO3 for photovoltaics: Multiscale analysis and SCAPS Modeling
No full textInternational audienceThis study investigates the influence of BiFeO3 (BFO) dimensionality, used as active layer, on the performance of perovskite-based solar cells (PSCs). The synthesized BFO architectures were characterized and revealed a strong correlation between dimensionality and material physical properties. SCAPS-1D simulations demonstrated that the BFO nanofiber-based device in the ITO/Zn2SnO4/BFO-NF/MoO3/W stacking configuration achieved high PV performance, with a power conversion efficiency (PCE) of 1.71% and open-circuit voltage (VOC) of 0.34 V, attributed to enhanced light absorption, lower bandgap (~2.13 eV), and effective light trapping. Electron affinities in the 4.77–4.97 eV range, were extracted using a Mulliken-based approach for accurate band alignment. These findings highlight the potential of dimensional engineering for future high-efficiency PSCs using doped or hybrid perovskite materials
Degenerations of CoHAs of 2-Calabi-Yau categories
No full textBy work of Davison and Meinhardt, the cohomological Hall algebra of a symmetric quiver with potential admits a geometrically defined filtration (the perverse filtration) whose associated graded is a supercommutative algebra. In the case of the triple quiver of a quiver with the canonical cubic potential, which corresponds to the preprojective algebra of the quiver via dimensional reduction, there is an additional filtration (the less perverse filtration), which is defined more generally for cohomological Hall algebras of suitably geometric 2-Calabi-Yau categories in work of Davison. In this paper, we show that the degenerations of the cohomological Hall algebras of preprojective algebras and more generally 2-Calabi-Yau categories with respect to the less perverse filtration is isomorphic to the enveloping algebra of the current Lie algebra of the BPS Lie algebra. This result applies in particular to CoHAs of local systems on Riemann surfaces and Higgs bundles on smooth projective curves. We extend this description to deformations of the cohomological Hall algebra obtained via torus actions on the arrows of the quiver and deformed canonical cubic potentials via the deformed dimensional reduction of Davison-Pȃdurariu. Last, we use our results to compare the less perverse filtration on CoHAs of preprojective algebras with the order filtration on the Maulik-Okounkov Yangian, via the comparison isomorphism of Botta-Davison and Schiffmann-Vasserot
« Nos pensionnaires sourds et muets » : l’abbaye Saint-Jean à Amiens au début du xviiie siècle
No full textInternational audienceDepuis les travaux de Théophile Denis à la fin du xixe siècle, au moins, l’abbaye Saint-Jean d’Amiens est identifiée comme un lieu d’écriture de l’expérience sourde au début du xviiie siècle. Dans cette abbaye de chanoines réguliers de l’ordre prémontré, Étienne de Fay (ca 1665-1746), lettré sourd prélingual, a connu un relatif renom de son vivant. Les témoignages de tiers ainsi que des archives écrites et dessinées continuent à susciter l’intérêt de ceux qui cherchent à rendre plus visible l’expérience sourde en France pendant la première modernité
Adaptive frequency separation-based energy management strategy using fuzzy logic for fuel cell-battery hybrid vehicles
No full textInternational audienc
Application of Li3InCl6-PEO Composite Electrolyte in All-Solid-State Battery
No full textInternational audiencePoly(ethylene oxide) (PEO)-based solid polymer electrolytes typically suffer from limited ionic conductivity at near-room temperature and often require inorganic reinforcement. Halide solid-state electrolytes such as Li3InCl6 (LIC) offer fast Li+ transport but are moisture-sensitive and typically require pressure-assisted densification. Here, we fabricate a flexible LIC–PEO composite electrolyte via slurry casting in acetonitrile with a small amount of LiPF6 additive. The free-standing membrane delivers an ionic conductivity of 1.19 mS cm−1 at 35 °C and an electrochemical stability window up to 5.15 V. Compared with pristine LIC, the composite shows improved moisture tolerance, and its conductivity can be recovered by mild heating after exposure. The electrolyte enables stable Li|LIC–PEO|Li cycling for >620 h and supports Li|LIC–PEO|NCM111 cells with capacity retentions of 84.2% after 300 cycles at 0.2 C and 80.6% after 150 cycles at 1.2 C (35 °C). Structural and surface analyses (XRD, SEM/EDX, XPS) elucidate the composite microstructure and interfacial chemistry
Validated Approach for Flow Cytometric Quantification of Phospholipase C Zeta (PLCζ, PLCZ1) Protein Levels in Sperm
No full textInternational audienceBackground/Objectives: Phospholipase C zeta (PLCZ1; PLCζ) is a sperm-specific enzyme responsible for the Ca2+ oscillations required for oocyte activation, and altered PLCζ expression has been associated with fertilization failure in assisted reproductive technologies, particularly intracytoplasmic sperm injection (ICSI). This study aimed to develop and analytically validate a flow cytometry–based protocol for PLCζ quantification in human spermatozoa. Methods: The assay was established using normozoospermic samples and included validated positive and negative technical controls. Antibody specificity was confirmed by Western blot analysis. A defined gating strategy was used to assess linearity between fluorescence intensity and PLCζ expression. Analytical performance was evaluated for precision, reproducibility, stability, and sensitivity, including applicability to low sperm concentrations. Results: A linear relationship between fluorescence intensity and PLCζ expression was demonstrated. The assay showed high precision, reproducibility, and stability, with consistent results in samples stored up to 24 h at room temperature or up to one week post-fixation at 4 °C. Sensitivity testing confirmed suitability for low sperm concentrations. Conclusions: This work provides a standardized and analytically validated framework for PLCζ quantification using flow cytometry. Although the assay measures protein expression rather than functional competence or subcellular localization, it establishes a solid analytical basis for future studies to define clinically relevant PLCζ thresholds and assess its value as a biomarker of fertilization capacity
P0805 Predictors of Endoscopic Remission at 1 Year in Patients with Ulcerative Colitis Treated with Guselkumab: Post-hoc Analyses of the QUASAR Trial
No full textInternational audienceBackground Ulcerative colitis (UC) management aims to achieve sustained clinical remission and long-term endoscopic and histological healing. In the Phase 2b/3 QUASAR trial in UC, guselkumab (GUS) significantly improved clinical remission by Week (W) 44 of the maintenance (M) study, with one-third of patients (pts) achieving endoscopic remission (ER; endoscopic Mayo subscore [EMS]=0).1 Post-hoc analyses of QUASAR evaluated predictors of ER at 1 year of GUS treatment in pts with moderately-to-severely active UC. Methods In the maintenance study of QUASAR, GUS (intravenous 200mg at W0, W4, and W8) responders at W12 of the induction study were re-randomized to receive subcutaneous (SC) GUS 100mg every 8W (Q8W), GUS 200mg SC Q4W, or placebo. Data from pts re-randomized to GUS were analyzed. Predictors of ER at M-W44 were assessed via logistic regression. Univariate models were run for each variable of interest at induction and M-baseline (BL). Variables with p < 0.1 were entered into reduced multivariate models using stepwise backward selection (Wald method); separate models were run for induction BL and M-BL variables. Results Of 378 GUS responders re-randomized to GUS 100mg SC Q8W or GUS 200mg SC Q4W, 129 (34%) achieved M-W44 ER. Rates of M-W44 ER did not differ across GUS regimens. In univariate models, induction BL factors associated with achieving M-W44 ER included female sex, extensive UC, concomitant oral aminosalicylate use, elevated C-reactive protein levels (CRP; >3mg/L), and no prior advanced drug therapy (ADT) failure (Table 1; Table 2). At M-BL, lower CRP (≤3mg/L or ≥ 50% reduction from induction BL) and fecal calprotectin (FC; ≤250μg/g or ≥ 50% reduction from induction BL) levels, and endoscopic healing (EMS=0 or 1) were also individually associated with M-W44 ER. After adjusting for GUS regimen, female sex (odds ratio [OR] [95% confidence interval; CI]: 1.8 [1.2, 2.9]; nominal P = 0.007), extensive UC (1.8 [1.2, 2.9]; nominal P = 0.007), and concomitant oral aminosalicylate use (1.9 [1.1, 3.4]; nominal P = 0.022) were identified as independent induction BL predictors of M-W44 ER. Achievement of endoscopic healing (3.1 [1.9, 4.9]; nominal P < 0.0001) at M-BL was independently associated with M-W44 ER. Conclusion Among GUS responders in the QUASAR maintenance study, female sex, extensive UC, and concomitant oral aminosalicylate use at induction BL were independently associated with ER at 1 year of GUS treatment. Importantly, achieving endoscopic healing after induction (i.e., at M-BL) was strongly associated with higher likelihood of ER at 1 year, irrespective of GUS dosing regimen, suggesting that this factor may help inform long-term endoscopic outcomes. Reference: 1. Rubin DT, Allegretti JR, Panés J, et al. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies. Lancet. 2025;405(10472):33-49. doi:10.1016/S0140-6736(24)01927-5. Conflict of interest: Rubin, David T.: Grant support: Takeda Pharmaceuticals Consultant: Abbvie, Abivax SA, Altrubio, Athos Therapeutics, Inc, Bristol-Myers Squibb, Celltrion, Connect BioPharma, Eli Lilly & Co., Genentech (Roche) Inc., Iterative Health, Janssen Pharmaceuticals, Johnson & Johnson, Merck & Co., Mirador, Odyssey Therapeutics, Pfizer, Sanofi, Spyre, Takeda Pharmaceuticals, Vedanta Biosciences, and Ventyx. Fumery, Mathurin: Grant: Pfizer Personal Fees: Abbvie, Janssen, Takeda, MSD, Biogen, Amgen, Sandoz, Fresenius, Gilead, Celgene, Galapagos, Mylan, Tillots, Ferring, Pfizer, Hospira, CTMA, Boehringer, Lilly, Arena Non-financial Support: Abbvie, Janssen, Takeda, MSD, Galapagos, Ferring, Pfizer Armuzzi, Alessandro: Consulting fees from AbbVie, Abivax, Alfa Sigma, Astra Zeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Eli-Lilly, Enthera, Ferring, Galapagos, Gilead, Giuliani, Janssen, Lionhealth, MSD, Nestlé, Pfizer, Protagonist Therapeutics, Roche, Samsung Bioepis, Sanofi, Sandoz, Takeda, Teva Pharmaceuticals, Tillots Pharma Speaker’s fees from AbbVie, Abivax, AG Pharma, Alfa Sigma, Biogen, Bristol-Myers Squibb, Celltrion, Eli-Lilly, Ferring, Galapagos, Gilead, Janssen, Lionhealth, MSD, Novartis, Pfizer, Roche, Samsung Bioepis, Sandoz, Takeda, Teva Pharmaceuticals Research support from Biogen, MSD, Takeda, and Pfizer Non-financial support from Abbvie, Janssen, MSD, Pfizer, Takeda Ferrante, Marc: Research grants from AbbVie, EG Pharma, Celltrion, Janssen, Pfizer, Takeda and Viatris Consultancy fees from AbbVie, AgomAb Therapeutics, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Janssen-Cilag, MRM Health, Merck Sharp and Dohme, Pfizer, Takeda and ThermoFisher Speakers’ fees from AbbVie, Biogen, Boehringer Ingelheim, Dr Falk Pharma, Ferring, Janssen-Cilag, Merck Sharp and Dohme, Pfizer, Takeda, Truvion Healthcare and Viatris Baker, Thomas: Employee of Johnson & Johnson Alvarez, Yelina: Employee of Johnson & Johnson Bravatà, Ivana: Employee of Johnson & Johnson Nazar, Maciek: Employee of Johnson & Johnson Van Denderen, Jacqueline: Employee of Johnson & Johnson Mccaffrey, Victoria: Employee of Johnson & Johnson Atreya, Raja: RA has served as a speaker, or consultant, or received research grants from AbbVie, Abivax, AlfaSigma, Arena Pharmaceuticals, Astra-Zeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion Healthcare, Dr Falk Pharma, Galapagos, Gilead, GlaxoSmithKline, InDex Pharmaceuticals, Johnson & Johnson, Lilly, Materia Prima, Merck Sharpe & Dohme, Pfizer, Roche Pharma, Takeda Pharma, Viatris
P1107 Comparison of effectiveness between ustekinumab and upadacitinib in patients with ulcerative colitis previously exposed to at least one anti-TNF agent: results from the real-world evidence multicenter UPPERCUT study
No full textInternational audienceBackground We compared the effectiveness of ustekinumab (UST) and upadacitinib (UPA) in patients with ulcerative colitis (UC) previously exposed to at least one anti-TNF agent. Methods This was a multicenter retrospective study that consecutively included all patients aged ≥18 years-old with symptomatic UC (partial Mayo score >2) who initiated UST or UPA after exposure to at least one anti-TNF. UST was initiated with an intravenous infusion followed by SC injections of 90 mg every 8 weeks, with the option of intensification to 90 mg every 4 weeks from week 4 at the clinician’s discretion. UPA was prescribed at 45 mg once daily for 8 weeks, followed by 45 mg, 30 mg, or 15 mg at the physician’s discretion. The primary endpoint was symptomatic remission (partial Mayo score ≤2) without corticosteroids (CFREM) at week 16 (W16). Secondary endpoints were clinical remission per modified Mayo score, and histological and endoscopic improvement (HEMI). Comparisons were made using propensity-score analyses adjusted on the usual potential confounders. Results A total of 226 patients were included (165 and 61 in UST and UPA groups, respectively). Except for higher proportion of prior exposure to more than two biologics (46.6% vs 82.0%; p < 0.001) in UPA group, the populations were comparable (UST vs UPA). After propensity score adjustment, CFREM at W16 was 35.1% and 37.2% in UST and UPA groups, respectively (p = 0.91). Subgroup analyses (after propensity adjustment) did not show any difference in CFREM at W16 after failure to only one biologic, whereas UPA was significantly more effective than UST (OR = 6.05 [1.10–33.42]; p = 0.039), after exposure to ≥ 2 advanced therapies, as well as in patients with primary failure to ≥ 2 prior biologics (OR = 4.25 [1.11–16.28]; p = 0.035). However, no difference was observed between the two treatments according to UC severity. No predictor of UPA effectiveness was identified. Factors associated with absence of CFREM at W16 under UST were: failure of ≥ 3 biologics (p = 0.013) and primary failure to at least one biologic (p = 0.013). No difference was observed between the two treatments regarding clinical remission and HEMI (p = 0.48 and 0.68, respectively). After a median follow-up > 12 months, we did not see any difference regarding treatment discontinuation, UC-related hospitalization, or colectomy. Conclusion In this study, UST and UPA appeared to have comparable effectiveness in the overall population of UC patients previously exposed to at least one anti-TNF. However, UPA was more effective than UST in patients exposed to at least two biologics and/or with at least two prior primary failures. These results may help physicians to personalize therapeutic decision-making in UC. Conflict of interest: Prof. Dr. Buisson, Anthony: Consulting fees from: Abbvie, AlfaSigma, Amgen, Arena, Biogen, Celltrion, CTMA, Ferring, Galapagos, Guty Care, Janssen, Hikma, Lilly, Mylan, Nexbiome, Pfizer, Roche, Takeda, Tillotts Lecture fees from: Abbvie, AlfaSigma, Amgen, Biogen, Celltrion, Ferring, Galapagos, Hikma, Janssen, Lilly, Mayoli-Spindler, MSD, Pfizer, Roche, Sanofi-Aventis, Takeda, Tillotts, Vifor-Pharma Research fundings from: Abbvie, AlfaSigma, Celltrion, Janssen, Lessaffre, Lilly, Pfizer, Takeda Serrero, Melanie: fees from Pfizer, Abbvie, Takeda, Janssen, MSD, Amgen, Ferring, Tillotts, Celltrion Altwegg, Romain: Advisory boards from Abbvie, Takeda, Johnson and Johnson, Lilly, Alphasigma, Celltrion, Pfizer, Amgen, Biogen, Sandoz, Ferring Vuitton, Lucine: No conflict of interest Uzzan, Mathieu: Grant: ECCO-IOIBD, Fondation pour la Recherche Medicale (FRM), SNFGE Personal Fees: Abbvie, Takeda, Celltrion, Janssen, Amgen, Alfasigma, Pfizer Domas, Quentin: No conflict of interest Tretón, Xavier: Personal Fees: Lectures and advisory board : Abbvie, Celltrion, MSD, johnson&Johnson, Takeda, Amgen, Alphasigma, Lilly, Pfizer Other: participations: Thabor Therapeutics Nachury, Maria: Abbvie, Alfa Sigma, Biosynex, Celltrion, Galapagos, Janssen, Lilly, MSD, Pfizer, Takeda Amiot, Aurelien: Personal Fees: Abbvie, Fresenius-Kabi, Adacyte, Tillotts pharma, Janssen, Pfizer, Biogen, AMgen, Sandoz, Takeda, Galapagos, Eli Lilly Caillo, Ludovic: Abbvie, Amgen, Celltrion, Ferring, Fresenius, Lilly, Jonhson&Jonhson, MSD, Pfizer, Takeda, Sandoz Hupé, Marianne: No conflict of interest Pereira, Bruno: No conflict of interest Fumery, Mathurin: Grant: Pfizer Personal Fees: Abbvie, Janssen, Takeda, MSD, Biogen, Amgen, Sandoz, Fresenius, Gilead, Celgene, Galapagos, Mylan, Tillots, Ferring, Pfizer, Hospira, CTMA, Boehringer, Lilly, Arena Non-financial Support: Abbvie, Janssen, Takeda, MSD, Galapagos, Ferring, Pfize